Ferrosa Therapeutics Secures Seed Financing for Innovative Anemia Treatment

Ferrosa Therapeutics AG, based in Basel, Switzerland, has announced a seed financing of USD 3.5 million, led by Forty51 Ventures. The funding aims to advance Ferrosa's bispecific antibody program tailored to treat anemia of inflammation prevalent in conditions such as chronic kidney disease, autoimmune disorders, and cancer.

This novel treatment targets cytokine-driven dysregulation of iron, a major factor in anemia, by combining two clinically validated pathways. Current therapies often address symptoms rather than root causes. Ferrosa's approach promises a more fundamental solution by correcting iron restrictions and enhancing erythropoiesis.

The company's CEO, Martin Stern, with a robust background in hematology and antibody development, leads the initiative. Notably, collaboration with experts in antibody engineering and nephrology strengthens Ferrosa’s effort to shift treatment from symptomatic to pathophysiological solutions.